ABBISKO-B (02256.HK): Chairman Xu Yaochang Raises Stake to 11.26%

NewTimeSpace News: On 11 November 2026, Abbisko Medicine Co., Ltd. (stock code: 2256) published a voluntary announcement that founder, executive director, chief executive officer and board chairman Dr Xu Yaochang informed the board that he bought a total of 145,000 ordinary shares on the open market on 11 November 2026 at an average price of about HK$6.67 per share, representing about 0.02% of the Company's total issued shares.

Following the purchase, Dr Xu holds interests in a total of 81,747,574 shares, representing about 11.26% of the total issued shares as at the date of the announcement.

Dr Xu is confident in the Group's business prospects and growth and does not rule out further increases in his shareholding at an appropriate time, subject to applicable laws and regulatory requirements. The Company confirmed that, following the purchase, it has complied with Rule 8.08 on maintaining a sufficient public float and that the purchase was made in accordance with the Model Code for securities transactions by directors in Appendix C3 to the Listing Rules; the purchase on 11 November was made after the Company had publicly disclosed the inside information on FDA approval of贝捷迈®.